Related Experiment Video
Updated: May 11, 2026
10:16
Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
Published on: February 8, 2017
Protein-coated nanoparticles embedded in films as delivery platforms
Javier O Morales1, Alistair C Ross, Jason T McConville
1College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.
The Journal of Pharmacy and Pharmacology
|May 8, 2013
Summary
Mucoadhesive films containing protein-coated nanoparticles effectively deliver macromolecules like lysozyme (Lys) via buccal administration. These nanoparticle-loaded films ensure protein stability and controlled release, showing promise for therapeutic applications.
Area of Science:
- Pharmaceutical Sciences
- Materials Science
- Biotechnology
Background:
- Macromolecule delivery systems are crucial for therapeutic applications.
- Nanoparticle formulations offer enhanced stability and targeted delivery.
- Polymethacrylates and hydroxypropylmethylcellulose (HPMC) are suitable matrices for drug delivery films.
Purpose of the Study:
- To evaluate nanoparticle-loaded films for macromolecule delivery.
- To assess the performance of polymethacrylate and HPMC matrices.
- To determine the suitability for buccal delivery of proteins and peptides.
Main Methods:
- Lysozyme (Lys)-loaded nanoparticles were prepared using antisolvent co-precipitation.
- Nanoparticles were characterized for size, loading efficiency, and stability.
- Nanoparticles were formulated into films with polymethacrylates (Eudragit RLPO) and HPMC for mechanical, mucoadhesive, and release studies.
Main Results:
- Protein-coated nanoparticles were successfully produced with high activity retention (99.2%).
- Films containing Eudragit RLPO and HPMC demonstrated excellent mechanical and mucoadhesive properties.
- Tailored, sustained release of Lys over 4 hours was achieved using a combination of Eudragit RLPO and HPMC, with preserved protein activity.
Conclusions:
- Mucoadhesive films incorporating protein-coated nanoparticles are effective carriers for buccal delivery.
- These systems ensure the stability of proteins and peptides during delivery.
- The developed films show significant potential for the stable buccal administration of therapeutic macromolecules.
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:27Drug Delivery Systems: Different Types
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...